Medipost
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Medipostco makes stem-cell-based treatments for knee cartilage damage and operates a cord-blood banking service that stores newborns' umbilical-cord blood for potential future medical use.
Its products and services reach patients, hospitals, and families in South Korea, with subsidiaries advancing clinical trials in North America and Japan. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the largest share of its revenue from cord-blood banking, with its stem-cell therapy for knee osteoarthritis, marketed as Cartistem, as its second major revenue contributor. It also supplies health supplements under a separate consumer brand.
Summary is AI-generated and may contain errors · figures from DART filings
Medipostco operates a dedicated contract development and manufacturing subsidiary, Medipostco CDMO, focused on cell and gene therapy manufacturing services.
Medipost in five facts
What does Medipost do?
Medipostco makes stem-cell-based treatments for knee cartilage damage and operates a cord-blood banking service that stores newborns' umbilical-cord blood for potential future medical use.
Where is Medipost listed and in which sector?
Medipost (Korean name: 메디포스트) trades under KRX code 078160 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Medipost?
Its market capitalisation was US$261M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Medipost's latest annual revenue and operating profit?
For fiscal year 2025, Medipost reported revenue of US$55.6M, an operating loss of US$51.3M and a net loss of US$64.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 4.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Proxy solicitation reference documentOct 14
- Notice of general shareholders' meetingOct 14
- Shareholder register closure / record date setSep 15
- Resolution to convene a general shareholders' meetingSep 15
- Decision to acquire shares/equity in another company
Medipost disclosed an acquisition of MEDIPOST, Inc., worth US$14.8M.
M&A · Jun 4 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Medipost reported consolidated results for FY2025: revenue of US$51M (+4.2% year on year), an operating loss of US$47.1M and a net loss of US$59.6M.
Earnings · Feb 23 - Decision to acquire shares/equity in another companyM&A · Jan 16
- [Amended] Material event report (convertible bonds)Capital raise · Jan 6
- [Amended] Material event report (convertible bonds)Capital raise · Jan 6
- [Amended] Material event report (convertible bonds)Capital raise · Jan 6
- [Amended] Material event report (convertible bonds)Capital raise · Jan 6